-
International Journal of Nanomedicine
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Water-soluble fullerene (c60) inhibits the development of arthritis in the rat model of arthritis
Original Research
(3179) Views (850) Full article downloads
Authors: Kazuo Yudoh, Rie Karasawa, Kayo Masuko, et al.
Published Date October 2009
Volume 2009:4 Pages 217 - 225
DOI: http://dx.doi.org/10.2147/IJN.S7653
Kazuo Yudoh1, Rie Karasawa1, Kayo Masuko2, Tomohiro Kato2
1Institute of Medical Science, 2Department of Biochemistry, St. Marianna University School of Medicine, Kawasaki, Japan
Abstract: Recently, it has been demonstrated that oxygen free radicals have an important role as a signaling messenger in the development of inflammation and osteoclastogenesis, suggesting the implication of oxygen free radicals in the pathogenesis of arthritis. The aim of this study was to examine the potential of a strong free-radical scavenger, water-soluble fullerene (C60), as a protective agent against synovitis in arthritis, both in vitro and in vivo. In the presence or absence of C60 (0.1, 1.0, 10.0 µM), human synovial fibroblasts, synovial infiltrating lymphocytes or macrophages were incubated with tumor necrosis factor-α (TNF-α) (10.0 ng/mL), and the production of proinflammatory cytokines by the individual cells were analyzed. C60 significantly suppressed the TNF-α-induced production of proinflammatory cytokines in synovial fibroblasts, synovial infiltrating lymphocytes and macrophages in vitro. Adjuvant induced arthritic rats were used as an animal model of arthritis. Rats were divided into two subgroups: control and treatment with C60 at 10.0 µM. The left ankle joint was injected intraarticularly with water-soluble C60 (20 µl) in the C60-treated group, while, as a control, the left ankle joint in the control rats received phosphate-buffered saline (20 µl), once weekly for eight weeks. Ankle joint tissues were prepared for histological analysis. In adjuvant-induced arthritic rats, intra-articular treatment with C60 in vivo reduced synovitis and alleviated bone resorption and destruction in the joints, while control ankle joints showed progression of synovitis and joint destruction with time. These findings indicate that C60 is a potential therapeutic agent for inhibition of arthritis.
Keywords: fullerene, inflammation, arthritis, synovitis, bone resorption
Other articles by Dr Kazuo Yudoh
Readers of this article also read:
Radiolucency below the crown of mandibular horizontal incompletely impacted third molars and acute inflammation in men with diabetes
Exacerbation rate, health status and mortality in COPD – a review of potential interventions
Berberine: metabolic and cardiovascular effects in preclinical and clinical trials
Water-soluble fullerene (C60) inhibits the osteoclast differentiation and bone destruction in arthritis
Biomedical applications of functionalized fullerene-based nanomaterials
Nanomedicine in pulmonary delivery
Amino acid management of Parkinson’s disease: a case study
Comparison of two treatments for coxarthrosis: local hyperthermia versus radio electric asymmetrical brain stimulation
Elucidation mechanism of different biological responses to multi-walled carbon nanotubes using four cell lines
- Have an opinion about one of our articles?
We encourage you to write a Letter to the Editor
- Interested in being a peer-reviewer?
Click here to register.
- Display new articles on your site
Use our widget to show articles on your own site
- Applications of gold nanoparticles in cancer nanotechnology
- Fungus-mediated biological synthesis of gold nanoparticles: potential in detection of liver cancer
- Gold nanoparticles: From nanomedicine to nanosensing
- Nanocarriers as pulmonary drug delivery systems to treat and to diagnose respiratory and non respiratory diseases




